HMGCR and neoplasm: Proprotein convertase subtilisin/kexin type 9 (PCSK9) and HMG-CoA reductase (HMGCR), both significantly high expressed in CRC tumor as ezetimibe potential targets (Figure 3), also confirmed of tight correlation to mTOR (Table 2).